International Multicentric Study ARON-1

This study looks at how well certain combination immunotherapy treatments work for people with kidney cancer (renal cell carcinoma) that has spread to other parts of the body. **You may be eligible if...** - You are over 18 years old - You have been diagnosed with kidney cancer (clear cell or non-clear cell type) confirmed by a biopsy or lab test - Your cancer has spread to other areas of your body (metastatic) - You have already received one of these specific first-line treatment combinations: nivolumab + ipilimumab, nivolumab + cabozantinib, pembrolizumab + axitinib, pembrolizumab + lenvatinib, avelumab + axitinib, or atezolizumab + bevacizumab **You may NOT be eligible if...** - Your kidney cancer diagnosis has not been confirmed by a biopsy or lab test - Your cancer has not been confirmed as metastatic (spread beyond the kidney) - You received an immunotherapy combination not listed above Talk to your doctor to see if this trial is right for you.